Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells

International Journal of Cancer

Volumn 127, Issue 5, 2010, Pages 1230-1239

  Lacroix, Jeannine ^a,b   Leuchs, Barbara ^a   Li, Junwei ^a   Hristov, Georgi ^a   Deubzer, Hedwig E ^a,b   Kulozik, Andreas E ^b   Rommelaere, Jean ^a   Schlehofer, Jörg R ^a   Witt, Olaf ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Apoptosis; Neuroblastoma; Oncolytic virus; Parvovirus H 1PV

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; INFECTION; LYSIS; MORPHOLOGY; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; ONCOGENE MYC; ONCOLYTIC VIROTHERAPY; PARVOVIRUS; PARVOVIRUS H1; PRIORITY JOURNAL; RODENT; SURVIVAL RATE; SURVIVAL TIME; VIRUS REPLICATION; ADULT; APOPTOSIS; ASTROCYTE; CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; GLIA; H-1 PARVOVIRUS; METABOLISM; NERVE CELL; NEUROBLASTOMA; PARVOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; VIROLOGY; WESTERN BLOTTING;

VIRUS DNA;

ADULT; APOPTOSIS; ASTROCYTES; BLOTTING, WESTERN; CELLS, CULTURED; DNA, VIRAL; FLOW CYTOMETRY; G1 PHASE; G2 PHASE; H-1 PARVOVIRUS; HUMANS; INFANT; NEUROBLASTOMA; NEUROGLIA; NEURONS; ONCOLYTIC VIROTHERAPY; PARVOVIRIDAE INFECTIONS; VIRUS REPLICATION;

EID: 77955482976     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25168     Document Type: Article

References (39)

1. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
2. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003;197:11-7.
3. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR, III, Fallon RJ, Rescorla FJ. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 2006;41:377-81.
4. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
5. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007;67:429-32.
6. Li QX, Liu G, Wong-Staal F. Oncolytic virotherapy as a personalized cancer vaccine. Int J Cancer 2008;123:493-9.
7. Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 2006;80:7522-34.
8. Toyoda H, Yin J, Mueller S, Wimmer E, Cello J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 2007;67:2857-64.
9. Li H, Dutuor A, Tao L, Fu X, Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 2007;13:316-22.
10. Farrell CJ, Zaupa C, Barnard Z, Maley J, Martuza RL, Rabkin SD, Curry WT, Jr. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res 2008;14:7711-6.
11. Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008;68:1170-9.
12. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009;4:e4235.
13. Parikh NS, Currier MA, Mahller YY, Adams LC, Di PB, Collins MH, Cripe TP. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005;44:469-78.
14. Chen YQ, Tuynder MC, Cornelis JJ, Boukamp P, Fusenig NE, Rommelaere J. Sensitization of human keratinocytes to killing by parvovirus H-1 takes place during their malignant transformation but does not require them to be tumorigenic. Carcinogenesis 1989;10:163-7.
15. Chen YQ, de Foresta F, Hertoghs J, Avalosse BL, Cornelis JJ, Rommelaere J. Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. Cancer Res 1986;46:3574-9.
16. Geletneky K, Herrero y Calle M, Rommelaere J, Schlehofer JR. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health 2005;52:327-30.
17. Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W, Rommelaere J, Galle PR, Cornelis JJ. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther 2001;8:158-67.
18. Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-Harig M, Ho AD, Rommelaere J, Raykov Z. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Mol Ther 2009;17:1164-72.
19. Di Piazza M, Mader C, Geletneky K, Herrero YC, Weber E, Schlehofer J, Deleu L, Rommelaere J. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol 2007;81:4186-98.
20. Cornelis JJ, Chen YQ, Spruyt N, Duponchel N, Cotmore SF, Tattersall P, Rommelaere J. Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription. J Virol 1990;64:2537-44.
21. Cornelis JJ, Salome N, Dinsart C, Rommelaere J. Vectors based on autonomous parvoviruses: novel tools to treat cancer? J Gene Med 2004;6 (Suppl 1): S193-S202.
22. Cotmore SF, Tattersall P. Parvoviral host range and cell entry mechanisms. Adv Virus Res 2007;70:183-232.
23. Caillet-Fauquet P, Perros M, Brandenburger A, Spegelaere P, Rommelaere J. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding nonstructural proteins. EMBO J 1990;9:2989-95.
24. Legrand C, Rommelaere J, Caillet-Fauquet P. MVM(p) NS-2 protein expression is required with NS-1 for maximal cytotoxicity in human transformed cells. Virology 1993;195:149-55.
25. Toolan HW, Saunders EL, Southam CM, Moore AE, Levin AG. H-1 virus viremia in the human. Proc Soc Exp Biol Med 1965;119:711-5.
26. Le Cesne A, Dupressoir T, Janin N. Intralesional administration of a live virus, parvovirus H1 (PVH-1) in cancer patients: a feasibility study. Proc Ann Meet Am Soc Clin Oncol 1993;12:297.
27. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009;15:511-9.
28. Raykov Z, Georgieva PB, Angelova A, Galabov AS, Rommelaere J. Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines. Acta Virol 2009;53:57-60.
29. Herrero y Calle M, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 2004;109:76-84.
30. Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 1989;49:3203-8.
31. van Pachterbeke C, Tuynder M, Cosyn JP, Lespagnard L, Larsimont D, Rommelaere J. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 1993;55:672-7.
32. van Pachterbeke C, Tuynder M, Brandenburger A, Leclercq G, Borras M, Rommelaere J. Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur J Cancer 1997;33:1648-53.
33. Wrzesinski C, Tesfay L, Salome N, Jauniaux JC, Rommelaere J, Cornelis J, Dinsart C. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003;77:3851-8.
34. Faisst S, Faisst SR, Dupressoir T, Plaza S, Pujol A, Jauniaux JC, Rhode SL, Rommelaere J. Isolation of a fully infectious variant of parvovirus H-1 supplanting the standard strain in human cells. J Virol 1995;69:4538-43.
35. Rayet B, Lopez-Guerrero JA, Rommelaere J, Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998;72:8893-903.
36. Brandenburger A, Legendre D, Avalosse B, Rommelaere J. NS-1 and NS-2 proteins may act synergistically in the cytopathogenicity of parvovirus MVMp. Virology 1990;174:576-84.
37. Ohshima T, Iwama M, Ueno Y, Sugiyama F, Nakajima T, Fukamizu A, Yagami K. Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. J Gen Virol 1998;79 (Pt 12):3067-71.
38. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50:4411-6.
39. Malerba M, Nikolova D, Cornelis J, Iggo R. Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter. Cancer Gene Ther 2006;13:273-80.